Montgomery based law firm Beasley, Allen, Crow, Methvin, Portis and Miles, P.C., has filed a second wrongful death lawsuit involving IV packs filled with liquid nutritional supplements that were contaminated. The lawsuit is filed on behalf of Lyndal Robinson, whose mother, Jewell Robinson, died after receiving contaminated total parenteral nutrition (TPN) at Shelby Baptist Medical Center in Shelby County, Alabama. The lawsuit names Birmingham-based pharmaceutical supplier Meds I.V. LLC as the primary defendant.

Montgomery based law firm Beasley, Allen, Crow, Methvin, Portis and Miles, P.C., has filed a wrongful death lawsuit on behalf of the family of a patient who died in an Alabama hospital after receiving intravenous (IV) fluid tainted with a bacterial infection. The lawsuit is filed on behalf of Barbara Young, whose mother, Mary Ellen Kise, died at Baptist Health Systems in Prattville, Ala.

Nine people died and 10 more were sickened in six Alabama hospitals after receiving IV packs filled with nutritional supplements that were contaminated with a dangerous bacteria. The supplement packs were compounded by a Birmingham pharmacy called Meds IV. Beasley Allen attorneys are investigating claims related to patient deaths as a result of receiving the tainted IV fluids.

Beasley, Allen, Crow, Methvin, Portis & Miles, P.C. attorney Navan Ward, Jr., who practices in the firm's Mass Torts section, has been chosen to help direct litigation related to the recall of 93,000 defective hip implant parts. Ward is one of 19 lawyers selected to oversee the consolidated litigation as part of the Plaintiffs Steering Committee (PSC).

It was announced this weekend that federal cases involving defective hip implant parts manufactured by DePuy Orthopaedics, a subsidiary of Johnson & Johnson, will be consolidated in federal court in the Northern District of Ohio under U.S. District Judge David A. Katz. The hip implant parts were recalled August 26 after research indicated patients who received the parts required a much higher than usual rate of revision surgeries.

The U.S. Food and Drug Administration has announced that Xanodyne Pharmaceuticals, inc., the maker of prescription pain medications Darvon and Darvocet, has agreed to withdraw the medications from the U.S. market. The move comes after the results of an FDA study in which new clinical data shows the drug, which goes by the generic name propoxyphene, puts patients at risk of potentially serious or even fatal heart rhythm abnormalities. The FDA determined the new data shows the risks of the drug outweigh any benefits.

Potent pain patches used to treat breakthrough pain in cancer patients already on around-the-clock pain medication are being recalled by the manufacturer because the patches may release too much of the painkiller Fentanyl which can lead to serious adverse events including death.